Previous 10 | Next 10 |
Yo-Yo dieting without additional treatment can explain high placebo response rates in NASH clinical trials Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced th...
New RENAsym platform helps drug developers avoid kidney injury side effects Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services divisio...
GastroPlus & ADMET Predictor software continue to drive gains for the company. Margins and renewal rates continue to increase. Services segment should return to growth due to strong pipeline activity. For further details see: Simulations Plus: Ample Momentum In Softw...
Ocugen (NASDAQ:OCGN) made it into the list of best healthcare performers this week as its development plans for the COVID-19 shot made progress in the U.S., while Cortexyme (NASDAQ:CRTX) lost more than a quarter of value after a disappointing outcome for an Alzheimer’s trial. The healt...
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced the release of version 9.8.2 of its flagship physiologically based biopharmaceutics (PBBM) / ...
The following slide deck was published by Simulations Plus, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Simulations Plus, Inc. 2021 Q4 - Results - Earnings Call Presentation
Collaboration will combine novel experimental techniques and mechanistic modeling strategies Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, today announced that, throu...
Simulations Plus, Inc. (SLP) Q4 2021 Results Earnings Conference Call October 25, 2021, 5:00 pm ET Company Participants Brian Siegel - Investor Relations, Managing Director at Hayden IR Shawn O'Connor - Chief Executive Officer Will Fredrick - Chief Financial Officer Conference Call Participan...
Image source: The Motley Fool. Simulations Plus, inc (NASDAQ: SLP) Q4 2021 Earnings Call Oct 25, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Simulations Plus, inc (SLP) Q4 2021 Earnings Call Transcript
Fiscal 2021 revenue increased 12% year-over-year to $46.5 million Software revenue increased 28% year-over-year to $27.7 million Fiscal 2022 financial outlook for total revenue of $51 million to $53 million, reflecting 10% to 15% year-over-year growth ...
News, Short Squeeze, Breakout and More Instantly...
Objective to define best practices for the use of novel PBK modeling strategies to support animal-free safety assessment of new chemicals Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance an...
Total revenue of $18.5 million and diluted earnings per share (EPS) of $0.15 Maintains full-year revenue guidance of $69 to $72 million and updates EPS guidance Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulati...
2024-06-24 16:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...